Codexis (CDXS)
NASDAQ:CDXS
CDXS Stock Chart & Stats
$1.75
-$0.29(-5.81%)
At close: 4:00 PM EST
$1.75
-$0.29(-5.81%)
Day’s Range― - ―
52-Week Range$0.96 - $3.87
Previous CloseN/A
Volume271.47K
Average Volume (3M)1.15M
Market Cap
$159.02M
Enterprise Value$181.44M
Total Cash (Recent Filing)$78.21M
Total Debt (Recent Filing)$73.21M
Price to Earnings (P/E)―
Beta1.77
Next Earnings
Apr 30, 2026EPS Estimate
-0.16Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.11
Shares Outstanding90,869,350
10 Day Avg. Volume1,704,148
30 Day Avg. Volume1,146,380
Financial Highlights & Ratios
PEG Ratio0.07
Price to Book (P/B)2.81
Price to Sales (P/S)2.02
P/FCF Ratio-5.96
Enterprise Value/Market Cap1.14
Enterprise Value/Revenue2.58
Enterprise Value/Gross Profit3.24
Enterprise Value/Ebitda-6.04
Forecast
1Y Price Target
$6.50Price Target Upside271.43% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering3
EPS Forecast (FY)-0.45
Revenue Forecast (FY)$74.98M
Bulls Say, Bears Say
Bulls Say
Balance Sheet And LiquiditySecured cash runway through 2027, supported by expected funds from the Merck agreement, reduces financing risk and enables continued investment in growth initiatives.
Customer Growth And PipelineAddition of ten new commercial customers and a pipeline of forty prospects indicates accelerating commercial traction and potential for diversified revenue sources.
Strategic PartnershipThe $37.8 million supply assurance agreement with Merck provides committed revenue that materially improves revenue visibility and supports commercial scale-up.
Bears Say
Commercial Transition RiskA prolonged transition to new products and services may postpone revenue acceleration and compress growth expectations.
Earnings And Financial PerformanceReported third-quarter results that fell short of expectations heighten concerns about near-term profitability and could sustain investor caution.
Workforce Reduction And Execution RiskElimination of 46 positions, roughly 24% of the workforce, may disrupt operations and increase execution risk during restructuring.
Codexis News
CDXS FAQ
What was Codexis’s price range in the past 12 months?
Codexis lowest stock price was $0.96 and its highest was $3.87 in the past 12 months.
What is Codexis’s market cap?
Codexis’s market cap is $159.02M.
When is Codexis’s upcoming earnings report date?
Codexis’s upcoming earnings report date is Apr 30, 2026 which is in 34 days.
How were Codexis’s earnings last quarter?
Codexis released its earnings results on Mar 11, 2026. The company reported $0.11 earnings per share for the quarter, beating the consensus estimate of -$0.03 by $0.14.
Is Codexis overvalued?
According to Wall Street analysts Codexis’s price is currently Undervalued.
Does Codexis pay dividends?
Codexis does not currently pay dividends.
What is Codexis’s EPS estimate?
Codexis’s EPS estimate is -0.16.
How many shares outstanding does Codexis have?
Codexis has 90,869,350 shares outstanding.
What happened to Codexis’s price movement after its last earnings report?
Codexis reported an EPS of $0.11 in its last earnings report, beating expectations of -$0.03. Following the earnings report the stock price went up 34.646%.
Which hedge fund is a major shareholder of Codexis?
Currently, no hedge funds are holding shares in CDXS
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Codexis Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$6.50 (271.43% Upside)
$6.50 (271.43% Upside)
Hedge Fund Trend
Increased
By 10.0K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $27.7K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 0.8%
Last 30 Days ▼ 5.4%
Last 30 Days ▼ 5.4%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-65.50%
12-Months-Change
Fundamentals
Return on Equity
-90.51%
Trailing 12-Months
Asset Growth
-0.81%
Trailing 12-Months
Company Description
Codexis
Codexis, Inc. discovers, develops, and sells enzymes and other proteins. It offers biocatalyst products and services; intermediate chemicals products that are used for further chemical processing; and Codex biocatalyst panels and kits that enable customers to perform chemistry screening. The company also provides biocatalyst screening and protein engineering services. In addition, it offers CodeEvolver protein engineering technology platform, which helps in developing and delivering biocatalysts that perform chemical transformations and enhance the efficiency and productivity of manufacturing processes. The company's platform is also used to discover novel biotherapeutic drug candidates for targeted human diseases, as well as for molecular biology and in vitro diagnostic enzymes. It sells its products to pharmaceutical manufacturers through its direct sales and business development force in the United States and Europe. The company was incorporated in 2002 and is headquartered in Redwood City, California.
CDXS Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call highlighted substantial technical progress and commercial momentum for the ECOsynthesis platform (notable scale-up milestones, ISO 9001 certification, CDMO agreements, and a 55-opportunity pipeline) and showed improved financial metrics (higher revenue, stronger product gross margins, reduced annual net loss, and a strengthened cash position aided by a ~ $37.8M Merck agreement). At the same time, important risks remain: ECOsynthesis revenue is currently service-heavy with limited margin contribution, full-year net loss persists, R&D investments and GMP capex will continue to pressure cash, and many commercial relationships remain in feasibility or assessment stages. Given the number and significance of technical and commercial achievements that materially de-risk the business combined with remaining near-term financial and execution uncertainties, the overall tone is cautiously optimistic.View all CDXS earnings summariesCDXS Stock 12 Month Forecast
Average Price Target
$6.50
▲(271.43% Upside)
Technical Analysis
Ownership Overview
13.58% Insiders
15.45% Mutual Funds
23.75% Other Institutional Investors
37.90% Public Companies and
Individual Investors